jcm-logo

Journal Browser

Journal Browser

PET/CT Imaging in Oncology: Clinical Updates and Prospects

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Nuclear Medicine & Radiology".

Deadline for manuscript submissions: 5 November 2025 | Viewed by 404

Special Issue Editor


E-Mail Website
Guest Editor
Division of Nuclear Medicine, Department of Radiology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA
Interests: radiomics; hetero-bivalent radioligand therapy; dosimetry

Special Issue Information

Dear Colleagues,

We are pleased to invite you to contribute to this Special Issue of Journal of Clinical Medicine, entitled “PET/CT Imaging in Oncology: Clinical Updates and Prospects”. In spite of recent advances, significant developments are still required in order to consider most, if not all, cancers curable ailments. The precise management of cancers requires timely detection of the cancer, and of both response and recurrence. Here, PET/CT employing various radiotracers has proven pivotal, as can be seen in its recommendation in the NCCN guidelines for various tumors. However, many areas of PET molecular imaging are undergoing active investigations to make progress in the detection of various molecular targets, and also to improve the general integration of molecular imaging into the workflow of oncologic management. This Special Issue focuses on clinical applications of PET/CT imaging in cancers and aims to cover future prospects in  PET imaging, including, but not limited to, newer radiotracers, artificial intelligence, novel targets, radiomics, and PET/CT in synchronous malignancies. We look forward to your contributions.

Dr. Ahmad Shariftabrizi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • new radiotracers
  • PET radiomics
  • CAR T-cell therapy
  • rare tumors
  • radiogenomics
  • immunotherapy outcome prediction
  • PET physics
  • normal tissue PET/CT
  • synchronous malignancies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

15 pages, 1371 KiB  
Systematic Review
The Usefulness of 2-[18F]FDG PET or PET/CT in Extranodal Natural Killer/T-Cell Lymphoma: A Systematic Review and Meta-Analysis
by Domenico Albano, Carlo Rodella, Alessandra Tucci, Giorgio Treglia, Francesco Bertagna, Arturo Chiti and Federico Fallanca
J. Clin. Med. 2025, 14(13), 4582; https://doi.org/10.3390/jcm14134582 - 27 Jun 2025
Viewed by 289
Abstract
Background/Objectives: Extranodal NK-/T-cell lymphoma (ENKTCL) is a rare and highly aggressive lymphoma with a bad prognosis. The aim of our analysis is to evaluate existing research on the potential usefulness of fluorine-18-fluorodeoxyglucose positron emission tomography or positron/computed tomography (2-[18F]FDG PET or PET/CT) in [...] Read more.
Background/Objectives: Extranodal NK-/T-cell lymphoma (ENKTCL) is a rare and highly aggressive lymphoma with a bad prognosis. The aim of our analysis is to evaluate existing research on the potential usefulness of fluorine-18-fluorodeoxyglucose positron emission tomography or positron/computed tomography (2-[18F]FDG PET or PET/CT) in the management of patients with ENKTCL. Methods: A complete search of the literature was conducted across Scopus, PubMed/MEDLINE, and Embase databases, focusing on articles published up to March 2025. Results: A total of 21 studies that investigated the role of 2-[18F]FDG PET or PET/CT in ENKTCL were included in our analysis. The main findings from the literature analysis were (1) 2-[18F]FDG PET/CT seems to be helpful in staging settings, showing a better diagnostic performance than conventional imaging and a positive impact on clinical stage; (2) 2-[18F]FDG PET/CT had excellent negative predictive value for detecting bone marrow involvement, especially in early-stage disease; and (3) qualitative and semiquantitative PET parameters might predict prognosis. Conclusions: Despite several limitations affecting this analysis, especially related to the heterogeneity of the studies included, 2-[18F]FDG PET/CT seems to be a useful tool for the evaluation of ENKTCL. Full article
(This article belongs to the Special Issue PET/CT Imaging in Oncology: Clinical Updates and Prospects)
Show Figures

Figure 1

Back to TopTop